Literature DB >> 35118313

System for thymic disease research and clinical practice in Japan.

Meinoshin Okumura1.   

Abstract

Japanese Association for Research of the Thymus (JART) established by emeritus professor Akira Masaoka is a cross-sectional association of physicians and researchers and have worked in clinical and basic research on thymic neoplasms and thymus-related diseases in collaboration with The Japanese Surgical Society (JSS), Japanese Association for Chest Surgery (JACS), Japanese Association for Thoracic Surgery (JATS), Japan Lung Cancer Society (JLCS), Japanese Respiratory Society (JRS) and Japanese Association for Respiratory Endoscopy (JARE). JART has performed several clinical trials, and the most important establishment of JART in recent days is the project of the nation-wide retrospective database of thymic epithelial tumors, which contributed to UICC TNM staging. Currently, JART is building the prospective database in collaboration with the Japanese Joint Committee for Lung Cancer Registry (JJCLCR). 2021 Mediastinum. All rights reserved.

Entities:  

Keywords:  Thymus; nation-wide database; thymic carcinoma; thymic epithelial tumor; thymoma

Year:  2021        PMID: 35118313      PMCID: PMC8794313          DOI: 10.21037/med-2020-04

Source DB:  PubMed          Journal:  Mediastinum        ISSN: 2522-6711


Several academic associations in Japan have been working together to research thymic diseases and apply those results to clinical practice, with the relationships of these associations and their functions shown in .
Figure 1

Associations related to thymic disease research and clinical practice in Japan.

Associations related to thymic disease research and clinical practice in Japan. The Japanese Surgical Society (JSS) is the largest association in the field of surgery in Japan and covers all fields, including gastrointestinal, liver, cardiac, general thoracic, breast, endocrine organ surgery, and pediatric surgery, as well as traumatology, with 39,742 members in 2019. General thoracic surgery accounts for 8% of the JSS, while they also belong to both the Japanese Association for Chest Surgery (JACS) and Japanese Association for Thoracic Surgery (JATS), with the latter group covering all fields of thoracic surgery (cardiovascular, esophageal, lung, mediastinal). Thus, active surgeons treating thymic diseases are members of JSS, JACS, and JATS concurrently. The Japan Lung Cancer Society (JLCS) was formed for physicians in all fields who treat lung cancer and thoracic malignancies. Also, the Japanese Association for Research of the Thymus (JART) is a cross-sectional association of physicians and researchers in the fields of thoracic surgery, medical oncology, neurology, radiology, pathology, and basic immunology, with 550 members in 2018. Most general thoracic surgeons and medical oncologists involved in treating lung cancer cases are also members of the Japanese Respiratory Society (JRS) and Japanese Association for Respiratory Endoscopy (JARE). JACS, JATS, JLCS, JRS, JARE, JART, and the Japan Asbestos Mesothelioma Interest Group (JAMIG) jointly operate the Japanese Joint Committee for Lung Cancer Registry (JJCLCR), which has constructed and maintains a nationwide database of lung cancer, thymic epithelial tumor, and malignant mesothelioma cases. The Japan Clinical Oncology Group (JCOG), which is independent of these academic associations, is supported by the Japanese government and conducts clinical trials, with JCOG 9605 and JCOG 9606 reported by Kunitoh et al. (1,2). Based on the advocacy of Prof. Akira Masaoka at Nagoya City University, JART was founded in 1982. Annual meetings are conducted, with the 39th meeting hosted by Prof. Atsushi Watanabe in Sapporo, Hokkaido, in 2019, during which 60 abstracts were presented. The “General Rules for Study of Mediastinal Tumors” was edited by the former president of JART, Professor Emeritus Yoshitaka Fujii at Nagoya City University, in 2009 ().
Figure 2

Cover of “General Rules for Study of Mediastinal Tumors”.

Cover of “General Rules for Study of Mediastinal Tumors”. JART has initiated three clinical trials. JART01, a prospective study of carboplatin + paclitaxel as chemotherapy for thymoma, was unfortunately discontinued because of the appearance of fatal myocarditis as a severe side effect (3). JART02 was conducted as a surgical trial to compare a partial with a subtotal thymectomy (4), while JART03, performed in collaboration with Lung Oncology Group in Kyushu (LOGIC), was a prospective study of cisplatin + TS1 + RT as chemoradiotherapy for locally advanced thymic carcinoma (5). Another important achievement by JART was development of a nationwide retrospective database of 2,793 thymic epithelial tumor cases surgically treated in Japan between 1991 and 2010. Thirty-two experienced institutes participated in the project. Findings of recurrence-free survival after a macroscopically complete resection according to pathological type are shown in . Ten research papers that used this database have been published in English language journals (6-15). The JART retrospective database also contributed to establishing UICC TNM staging in collaboration with ITMIG and IASLC (16). Presently, JART and JJCLCR are concurrently building a prospective database of thymic epithelial tumor cases.
Figure 3

Results acquired from JART retrospective database regarding recurrence-free survival after a macroscopically complete resection according to pathological type. JART, Japanese Association for Research of the Thymus.

Results acquired from JART retrospective database regarding recurrence-free survival after a macroscopically complete resection according to pathological type. JART, Japanese Association for Research of the Thymus. JART has played an important role for communication with global societies. Further collaborations among Japanese societies and international associations are expected, and will contribute to advancement in research of thymic diseases.
  16 in total

1.  The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors.

Authors:  Frank C Detterbeck; Kelly Stratton; Dorothy Giroux; Hisao Asamura; John Crowley; Conrad Falkson; Pier Luigi Filosso; Aletta A Frazier; Giuseppe Giaccone; James Huang; Jhingook Kim; Kazuya Kondo; Marco Lucchi; Mirella Marino; Edith M Marom; Andrew G Nicholson; Meinoshin Okumura; Enrico Ruffini; Paul Van Schil
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

2.  Video-Assisted Thoracic Surgery Thymectomy Versus Sternotomy Thymectomy in Patients With Thymoma.

Authors:  Hiroyuki Agatsuma; Kazuo Yoshida; Ichiro Yoshino; Meinoshin Okumura; Masahiko Higashiyama; Kenji Suzuki; Masanori Tsuchida; Jitsuo Usuda; Hiroshi Niwa
Journal:  Ann Thorac Surg       Date:  2017-06-13       Impact factor: 4.330

3.  Is Thymomectomy Alone Appropriate for Stage I (T1N0M0) Thymoma? Results of a Propensity-Score Analysis.

Authors:  Kazuo Nakagawa; Kohei Yokoi; Jun Nakajima; Fumihiro Tanaka; Yoshimasa Maniwa; Makoto Suzuki; Takeshi Nagayasu; Hisao Asamura
Journal:  Ann Thorac Surg       Date:  2015-10-17       Impact factor: 4.330

4.  Mortality from extrathymic malignancy after thymic tumour resections: incidences and risk factors.

Authors:  Masatsugu Hamaji; Takashi Sozu; Ryunosuke Machida; Shun-Ichi Watanabe; Kazuo Yoshida; Shinichi Toyooka; Masayuki Tanahashi; Kazuya Kondo; Hirotoshi Horio; Meinoshin Okumura; Hiroshi Date
Journal:  Interact Cardiovasc Thorac Surg       Date:  2019-11-01

5.  Surgical Outcomes of Patients With Stage III Thymoma in the Japanese Nationwide Database.

Authors:  Yoshito Yamada; Ichiro Yoshino; Jun Nakajima; Shinichiro Miyoshi; Takamasa Ohnuki; Makoto Suzuki; Takeshi Nagayasu; Akinori Iwasaki; Meinoshin Okumura
Journal:  Ann Thorac Surg       Date:  2015-07-07       Impact factor: 4.330

6.  Thymoma patients with pleural dissemination: nationwide retrospective study of 136 cases in Japan.

Authors:  Katsuhiro Okuda; Motoki Yano; Ichiro Yoshino; Meinoshin Okumura; Masahiko Higashiyama; Kenji Suzuki; Masanori Tsuchida; Jitsuo Usuda; Hisashi Tateyama
Journal:  Ann Thorac Surg       Date:  2014-03-20       Impact factor: 4.330

7.  A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606).

Authors:  H Kunitoh; T Tamura; T Shibata; K Takeda; N Katakami; K Nakagawa; A Yokoyama; Y Nishiwaki; K Noda; K Watanabe; N Saijo
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

8.  Surgical management of recurrent thymic epithelial tumors: a retrospective analysis based on the Japanese nationwide database.

Authors:  Tetsuya Mizuno; Meinoshin Okumura; Hisao Asamura; Kazuo Yoshida; Hiroshi Niwa; Kazuya Kondo; Hirotoshi Horio; Akihide Matsumura; Kohei Yokoi
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609

9.  Myasthenia gravis with thymic epithelial tumour: a retrospective analysis of a Japanese database.

Authors:  Jun Nakajima; Meinoshin Okumura; Motoki Yano; Hiroshi Date; Takuya Onuki; Masayuki Haniuda; Yoshifumi Sano
Journal:  Eur J Cardiothorac Surg       Date:  2015-11-03       Impact factor: 4.191

10.  A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605).

Authors:  H Kunitoh; T Tamura; T Shibata; K Nakagawa; K Takeda; Y Nishiwaki; Y Osaki; K Noda; A Yokoyama; N Saijo
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.